JP2008531647A - 抗腫瘍作用を有する製剤 - Google Patents
抗腫瘍作用を有する製剤 Download PDFInfo
- Publication number
- JP2008531647A JP2008531647A JP2007557486A JP2007557486A JP2008531647A JP 2008531647 A JP2008531647 A JP 2008531647A JP 2007557486 A JP2007557486 A JP 2007557486A JP 2007557486 A JP2007557486 A JP 2007557486A JP 2008531647 A JP2008531647 A JP 2008531647A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- antitumor activity
- defibrotide
- tumor
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
本明細書中では、語オリゴチドは、4000-10000ダルトンの分子量を有する任意のオリゴデオキシリボヌクレオチドを指すために用いられる。好ましくは、それは、以下の分析パラメーターを有する任意のオリゴデオキシリボヌクレオチドを指す。
分子量(mw):4000-10000ダルトン、
濃色効果(h):<10、
A+T/C+G:1.100-1.455、
A+G/C+T:0.800-1.160、
比旋光度: +30°− +46.8°、好ましくは +30°− +46.2°
オリゴチドは、動物および/または植物の組織から、特に、哺乳動物の器官からの抽出により作成されうる、あるいは合成的に作成されうる。好ましくは、抽出により作成されるときは、引用することにより本明細書に組み入れられる(1)、(2)、および(3)に記載された方法に従ってそれは得られる。オリゴチドは、顕著な抗虚血活性を持っているとして知られている。
Claims (12)
- 抗腫瘍作用を有する製剤の製造のために、4000-10000ダルトンの分子量を有するオリゴデオキシリボヌクレオチドを使用する方法。
- 該オリゴデオキシリボヌクレオチドが以下の分析パラメーターを有することを特徴とする、請求項1に記載の方法。
h(濃色効果) <10
A+T/C+G:1.100-1.455
A+G/C+T:0.800-1.160
比旋光度: +30°− +46.8° - 比旋光度が+30°および+46.2°の間にあることを特徴とする、請求項2に記載の方法。
- 該オリゴデオキシリボヌクレオチドが、動物および/または植物の組織から、好ましくは哺乳動物の器官からの抽出により得られることを特徴とする、請求項1に記載の方法。
- 該オリゴデオキシリボヌクレオチドが、合成的に得られることを特徴とする、請求項1に記載の方法。
- 該製剤が哺乳動物に投与されるものであることを特徴とする、請求項1に記載の方法。
- 該哺乳動物がヒトであることを特徴とする、請求項1に記載の方法。
- 該製剤が静脈から投与されるものであることを特徴とする、請求項1に記載の方法。
- 該製剤が水溶液であることを特徴とする、請求項1に記載の方法。
- 該製剤が抗腫瘍作用を有する少なくとも1の他の活性成分を含むことを特徴とする、請求項1に記載の方法。
- 抗腫瘍作用を有する該他の活性成分が、デフィブロチド、ラパマイシン、パクリタキセル、モノクロタリン、BCNU、および/またはシクロホスファミドから選択されることを特徴とする、請求項10に記載の方法。
- 該製剤が慣用の賦形剤および/または助剤を含むことを特徴とする、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000336A ITMI20050336A1 (it) | 2005-03-03 | 2005-03-03 | Formulazione ad attivita' anti-tumorale |
US73140405P | 2005-10-28 | 2005-10-28 | |
PCT/EP2006/060306 WO2006094917A2 (en) | 2005-03-03 | 2006-02-27 | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531647A true JP2008531647A (ja) | 2008-08-14 |
JP2008531647A5 JP2008531647A5 (ja) | 2009-04-02 |
Family
ID=36572331
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557486A Pending JP2008531647A (ja) | 2005-03-03 | 2006-02-27 | 抗腫瘍作用を有する製剤 |
JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび/またはオリゴデオキシリボヌクレオチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび/またはオリゴデオキシリボヌクレオチド |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080194507A1 (ja) |
EP (2) | EP1855697A2 (ja) |
JP (2) | JP2008531647A (ja) |
KR (3) | KR20070120953A (ja) |
AU (2) | AU2006222044A1 (ja) |
CA (2) | CA2598613A1 (ja) |
IL (3) | IL185181A0 (ja) |
MX (2) | MX2007010407A (ja) |
WO (2) | WO2006094916A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
US8187897B2 (en) | 2008-08-19 | 2012-05-29 | International Business Machines Corporation | Fabricating product chips and die with a feature pattern that contains information relating to the product chip |
ES2694239T3 (es) | 2010-11-12 | 2018-12-19 | Gentium S.R.L. | Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD) |
KR102038357B1 (ko) | 2012-06-22 | 2019-10-31 | 젠티엄 에스알엘 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
TW201909904A (zh) | 2017-08-03 | 2019-03-16 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 高濃度調配物 |
WO2019200251A1 (en) | 2018-04-12 | 2019-10-17 | Jazz Pharmaceuticals, Inc. | Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion |
WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
WO2021174039A1 (en) | 2020-02-28 | 2021-09-02 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
WO2022234101A1 (en) | 2021-05-06 | 2022-11-10 | Jazz Pharmaceuticals Ireland Limited | Defibrotide for the treatment and prevention of acute respiratory distress syndrome |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05247083A (ja) * | 1991-12-09 | 1993-09-24 | Crinos Ind Farmacobiolog Spa | 抗虚血活性を有する新規なオリゴデオキシリボヌクレオチド類およびその製造方法 |
WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
US5919772A (en) * | 1993-12-01 | 1999-07-06 | Mcgill University | Antisense oligonucleotides having tumorigenicity-inhibiting activity |
JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Dnaメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
-
2006
- 2006-02-27 JP JP2007557486A patent/JP2008531647A/ja active Pending
- 2006-02-27 AU AU2006222044A patent/AU2006222044A1/en not_active Abandoned
- 2006-02-27 JP JP2007557485A patent/JP5714203B2/ja not_active Expired - Fee Related
- 2006-02-27 KR KR1020077021110A patent/KR20070120953A/ko not_active Application Discontinuation
- 2006-02-27 EP EP06708537A patent/EP1855697A2/en not_active Withdrawn
- 2006-02-27 MX MX2007010407A patent/MX2007010407A/es not_active Application Discontinuation
- 2006-02-27 WO PCT/EP2006/060304 patent/WO2006094916A1/en active Application Filing
- 2006-02-27 MX MX2007010754A patent/MX2007010754A/es not_active Application Discontinuation
- 2006-02-27 CA CA002598613A patent/CA2598613A1/en not_active Abandoned
- 2006-02-27 AU AU2006222045A patent/AU2006222045B2/en not_active Ceased
- 2006-02-27 KR KR1020077023861A patent/KR20070121001A/ko not_active Application Discontinuation
- 2006-02-27 CA CA2598072A patent/CA2598072C/en not_active Expired - Fee Related
- 2006-02-27 US US11/817,575 patent/US20080194507A1/en not_active Abandoned
- 2006-02-27 US US11/817,572 patent/US20080194506A1/en not_active Abandoned
- 2006-02-27 KR KR1020077021114A patent/KR20070120954A/ko not_active Application Discontinuation
- 2006-02-27 EP EP06708536A patent/EP1853277A1/en not_active Ceased
- 2006-02-27 WO PCT/EP2006/060306 patent/WO2006094917A2/en active Application Filing
-
2007
- 2007-08-09 IL IL185181A patent/IL185181A0/en unknown
- 2007-08-09 IL IL185182A patent/IL185182A0/en active IP Right Grant
- 2007-08-14 IL IL185258A patent/IL185258A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05247083A (ja) * | 1991-12-09 | 1993-09-24 | Crinos Ind Farmacobiolog Spa | 抗虚血活性を有する新規なオリゴデオキシリボヌクレオチド類およびその製造方法 |
US5919772A (en) * | 1993-12-01 | 1999-07-06 | Mcgill University | Antisense oligonucleotides having tumorigenicity-inhibiting activity |
WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Dnaメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
Also Published As
Publication number | Publication date |
---|---|
IL185258A (en) | 2010-12-30 |
IL185182A0 (en) | 2008-01-20 |
KR20070120953A (ko) | 2007-12-26 |
CA2598072A1 (en) | 2006-09-14 |
WO2006094917A2 (en) | 2006-09-14 |
CA2598613A1 (en) | 2006-09-14 |
IL185181A0 (en) | 2008-01-20 |
MX2007010754A (es) | 2007-11-07 |
MX2007010407A (es) | 2007-10-17 |
IL185258A0 (en) | 2008-02-09 |
CA2598072C (en) | 2016-05-03 |
KR20070120954A (ko) | 2007-12-26 |
JP2008531646A (ja) | 2008-08-14 |
EP1853277A1 (en) | 2007-11-14 |
KR20070121001A (ko) | 2007-12-26 |
WO2006094917A8 (en) | 2008-01-31 |
WO2006094916A1 (en) | 2006-09-14 |
EP1855697A2 (en) | 2007-11-21 |
AU2006222045B2 (en) | 2011-10-20 |
AU2006222045A1 (en) | 2006-09-14 |
US20080194506A1 (en) | 2008-08-14 |
US20080194507A1 (en) | 2008-08-14 |
AU2006222044A1 (en) | 2006-09-14 |
JP5714203B2 (ja) | 2015-05-07 |
WO2006094917A3 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5714203B2 (ja) | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび/またはオリゴデオキシリボヌクレオチド | |
Hou et al. | Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis | |
Li et al. | Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs | |
Schlundt et al. | Macrophages in bone fracture healing: their essential role in endochondral ossification | |
Berta et al. | Apelin promotes lymphangiogenesis and lymph node metastasis | |
CN107108686A (zh) | 用于恶性肿瘤的rna干扰组合物和方法 | |
Zhang et al. | Hesperetin prevents bone resorption by inhibiting RANKL-induced osteoclastogenesis and Jnk mediated Irf-3/c-Jun activation | |
EP3569697B1 (en) | Stem cell therapy in endometrial pathologies | |
Ran et al. | Aquaporin-1 expression and angiogenesis in rabbit chronic myocardial ischemia is decreased by acetazolamide | |
CN105194651B (zh) | Creg蛋白用于保护心肌缺血再灌注损伤的医药用途 | |
Tanaka et al. | Circulating progenitor cells contribute to neointimal formation in nonirradiated chimeric mice | |
JP7039470B2 (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター4(mct4)アンチセンスオリゴヌクレオチド(aso)阻害剤 | |
JP2022113802A (ja) | 心不全の治療方法 | |
Hsu et al. | Micro RNA let‐7g possesses a therapeutic potential for peripheral artery disease | |
Segaliny et al. | Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells | |
Delfan et al. | High-intensity interval training improves cardiac function by miR-206 dependent HSP60 induction in diabetic rats | |
Wei et al. | PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-II diagnostic imaging and radiosensitization | |
Pidala et al. | Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial | |
Fu et al. | Mild magnetothermal enhanced nanocatalytic immunotherapy for solid tumors by immune cell activation and intratumoral infiltration | |
Van Der Elst et al. | Quantitative study of liver metastases from colon cancer in rats after treatment with cyclosporine A | |
Feng et al. | Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions | |
JP2012502934A (ja) | 病理的血管新生を阻害する組成物 | |
KR20200016163A (ko) | 사멸화 세포 처리 대식 세포 유래 엑소좀을 포함하는 암 예방 또는 치료용 조성물 | |
Chung et al. | Antibody to interleukin-6 receptor inhibits in vivo growth of human colorectal carcinoma cell xenografts | |
US10801025B2 (en) | MicroRNA therapy for pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120210 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120608 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120709 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130730 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130906 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131011 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140512 |